Skip to content

EV / EBITDA at other companies

Baxter International logo
Baxter InternationalBAX
10.3×-1.6×
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
12.3×-6.5×
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
13.3×-4.0×
Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
6.8×+0.5×
UFP Technologies logo
UFP TechnologiesUFPT
14×-2.6×
ICU Medical logo
ICU MedicalICUI
17.4×+0.4×

Other financials

Income statement

See full
Revenue$33.7M-3.0%
Gross profit$19.7M+2.7%
Operating income$1.6M+157%
Net income$1.0M+481%
EPS (diluted)$0.05+600%

Balance sheet

See full
Cash & equivalents$2.1M+39.8%
Total debt$24.1M-30.4%
Total equity$58.7M+6.5%
Total assets$98.7M-5.4%

Cash flow

See full
Operating cash flow$970.0K-45.5%
CapEx$157.0K+19.8%
Free cash flow$813.0K-50.7%

Valuation

See full
Market cap$205.05M+51.3%
Enterprise value$227.04M+36.2%
P/E25.9×-0.8×
P/S1.4×+0.5×

Profitability

See full
Gross margin56.7%+3.6pp
Operating margin9.1%+3.0pp
Net margin5.6%+3.2pp
FCF margin16.2%+1.0pp

Returns & leverage

See full
Return on equity13.9%+8.0pp
Debt / equity0.4×-0.2×
Current ratio2.1×-0.1×

Where this comes from

Calculated from InfuSystem Holdings’s reported figures.

Based on the most recent quarter.

The official record: InfuSystem Holdings’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about InfuSystem Holdings's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is InfuSystem Holdings's EV / EBITDA?
InfuSystem Holdings (INFU) reported EV / EBITDA of 8× in Q1 2026.
How has InfuSystem Holdings's EV / EBITDA changed year-over-year?
InfuSystem Holdings's EV / EBITDA increased by 16.2% year-over-year, from 6.9× to 8×.
What is the long-term trend for InfuSystem Holdings's EV / EBITDA?
Over 5 years (2020 to 2025), InfuSystem Holdings's EV / EBITDA has grown at a -15.0% compound annual growth rate (CAGR), from 18.2× to 8.1×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.